<DOC>
	<DOCNO>NCT00014196</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus radiation therapy treat patient stage IIIB non-small cell lung cancer .</brief_summary>
	<brief_title>S0022 : Combination Chemotherapy Radiation Therapy Treating Patients With Stage IIIB Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine survival time treatment failure patient stage IIIB non-small cell lung cancer treat induction docetaxel , cisplatin , radiotherapy follow consolidation docetaxel . - Determine response rate patient treat regimen . - Determine toxic effect regimen patient . OUTLINE : This multicenter study . Patients receive induction chemotherapy comprise docetaxel IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 cisplatin IV 60 minute day 1 , 8 , 29 , 36 . Patients also undergo concurrent radiotherapy daily , 5 day per week , 6.5 week . At least 1 week 4 week completion induction chemoradiotherapy , patient stable respond disease receive docetaxel IV 60 minute day 1 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Patients follow every 2 month 1 year , every 3 month 1 year , every 6 month 1 year . PROJECTED ACCRUAL : A total 90 patient accrue study within 30 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IIIB nonsmall cell lung cancer Adenocarcinoma Large cell carcinoma Squamous cell carcinoma Pathologically radiographically document positive N3 nod No positive supraclavicular scalene lymph node disease extend cervical region OR T4 tumor invade follow : Mediastinum Heart Great vessel Trachea Esophagus Vertebral body Carina No brain , contralateral chest , liver , adrenal metastases No 1 parenchymal lesion No malignant pleural effusion unless visible CT scan deem small tap No pericardial effusion Measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Not specify Renal : Creatinine clearance least 50 mL/min Pulmonary : One following : FEV1 least 2.0 L Predicted FEV1 contralateral lung great 800 mL Predicted posttreatment FEV1 least 1.0 L Other : No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent growth factor induction chemoradiotherapy Chemotherapy : No prior chemotherapy lung cancer Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy lung cancer Surgery : No prior surgical resection lung cancer Prior exploratory thoracotomy , mediastinoscopy , excisional biopsy , similar surgery determine diagnosis , stage , potential resectability allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>